国际皮肤性病学杂志    2005 31 (1): 24-26   ISSN: 2096-5540  CN: 32-1880/R   白塞病的某些治疗进展 宗文凯, 崔盘根 中国医学科学院、中国协和医科大学皮肤病研究所 南京 210042 收稿日期 2004-06-24  修回日期 null  网络版发布日期 null 参考文献  [1] Sakane T, Takeno M, Suzuki N, et al. Behcet's disease. N Engl J Med, 1999, 341:1284-1291. [2] Hirohata S, Kikuchi H. Behcet's disease. Arthritis Res Ther, 2003,5:139-146. [3] Evereklioglu C. Managing the symptoms of Behcet's disease. Expert Opin Pharmacother, 2004, 5:317-328. [4] Yazici H. Behcet's syndrome:where do we stand? Am JMed, 2002,112:75-76. [5] No authors listed. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet, 1990, 335:1078-1080. [6] Sakane T, Takeno M. Current therapy in Behcet's disease. Skin Therapy Lett, 2000,5:3-5. [7] Calguneri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease. Derm atology, 1996,192:125-128. [8] Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med, 1990, 322:281-285. [9] Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome:effects on long-term prognosis. Arthritis Rheum, 1997,40:769-774. [10] Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized,double-blind, placebo-controlled trial. Ann Intern Med, 1998, 128:443-450. [11] O'Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med, 1984, 76:75-84. [12] Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet, 1989, 1:1093-1096. [13] Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol, 1994, 118:39-45. [14] Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha 2b treatment in Behcet's syndrome. J Rheumatol, 1994,21:1098-1100. [15] Wechsler B, Du-Boutin LT. Interferons and Behcet's disease. Rev Med Interne, 2002,23:S495-S499. [16] Kotter I, Gunaydin I, Zierhut M,et al. The use of interferon alpha in Behcet disease:review of the literature. Semin Arthritis Rheum,2004,33:320-335. [17] Kattsambis AD. European Handbook of Dermatological Treatment.Berlin:Springer, 1999.21-30. [18] Mahe E, Descamps V. Anti-TNF alpha in dermatology. Ann Dermatol Venereol, 2002, 129:1374-1379. [19] Goossens PH, Verburg RJ, Breedveld FC. Remission of Behcet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis, 2001, 60:637. [20] Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology (Oxford),2001, 40:473-474. [21] Hassard PV, Binder SW, Nelson V,et al. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease:a case report. Gastroenterology, 2001, 120:995-999. [22] Travis SP, Czajkowski M, McGovern DP, et al. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut, 2001,49:725-728. [23] Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet,2001, 358:1644. [24] Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet,2001, 358:295-296. [25] Simsek H, Dundar S,Telatar H. Treatment of Behcet disease with indomethacin. Int J Dermatol, 1991,30:54-57. 通讯作者: